New Breast Cancer Drug Shows Modest Survival Benefit
A new clinical trial shows potential for patients with metastatic breast cancer, though risks of lung issues were noted.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Should pharmaceutical companies focus more on developing treatments with significant benefits than potentially limited ones?
BioNTech and DualityBio have reported results from a Phase 3 clinical trial for the drug candidate trastuzumab pamirtecan in patients with metastatic breast cancer. The trial met its primary endpoint of progression-free survival, though overall survival data remains immature.
Why it matters
This development represents a new experimental option for patients with HR+/HER2-low metastatic breast cancer who have progressed on endocrine therapy. Understanding these results is crucial for patients as researchers evaluate the drug's safety profile and efficacy.
In a Phase 3 randomized trial of 541 patients, trastuzumab pamirtecan showed a modest improvement in progression-free survival compared to chemotherapy. The final overall survival data is not yet mature and remains under investigation.
The players
BioNTech
A biotechnology company based in Mainz, Germany, focused on developing individualized immunotherapies for cancer and infectious diseases.
DualityBio
A Shanghai, China-based company specializing in the development of next-generation antibody-drug conjugates for oncology.
The details
The trial evaluated chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer who previously progressed on endocrine therapy. Patients were randomized 1:1 to receive either the study drug or physician-selected chemotherapy. While progression-free survival improved, researchers observed a higher rate of interstitial lung disease, including Grade 3-5 events, compared to data from earlier trials.
Timeline
October 26, 2026: BioNTech and DualityBio announced the clinical trial results.
Health Landscape
This trial follows the broader industry trend of targeting HER2-low expression in metastatic breast cancer. It updates the landscape of available therapies by testing a new agent against established chemotherapy protocols.
Patients currently undergoing treatment for metastatic breast cancer should discuss these interim results with their oncologist to understand how they compare to current standard-of-care options. It is important to monitor for potential lung-related symptoms, such as cough or shortness of breath, which warrant prompt medical attention.
The takeaway
While these trial results indicate potential for a new treatment pathway, the emergence of serious lung inflammation is a critical factor for patients and doctors to weigh. Continue tracking updates on this drug, as the companies are currently evaluating further clinical trial data to determine future steps.
Further reading
For more on evolving research in this field, visit our guide to Cancer.
Live Poll
Should pharmaceutical companies focus more on developing treatments with significant benefits than potentially limited ones?
